Whole Foods acquires Wild Oats
This article was originally published in The Tan Sheet
Executive Summary
Whole Foods completes its $565 mil. purchase of Wild Oats Markets, assuming debt of approximately $137 mil., the firm announces Aug. 28. The company initially purchased 84.1% of the firm's outstanding common share in a cash tender offer and will acquire as delivered approximately 12.7% of outstanding share of the firm's common stock. Whole Foods has entered into a five-year, $700 mil. senior term loan agreement to fund the transaction, and has signed a new revolving credit agreement. The companies announced plans for the merger in February, but the transaction was delayed when the Federal Trade Commission filed a complaint against the deal in June, concerned it would result in higher prices and reduced quality and services in the natural and organic foods retail market ("The Tan Sheet" June 11, 2007, In Brief)...
You may also be interested in...
Merger indigestion
The U.S. Court of Appeals for the District of Columbia Circuit reverses a district court ruling that denied a Federal Trade Commission injunction against Whole Foods' purchase of Wild Oats Markets. According to the July 29 1decision, the lower court erred in finding the merger could not result in a monopoly in any relevant product market because FTC would never be able to adequately define the "premium, natural and organic supermarkets" sector. The appeals decision says the district court "underestimated" the likelihood in FTC defining the PNOS market. FTC's general counsel July 30 said Whole Foods can seek a rehearing in the D.C. circuit before the same panel or en banc, submit a writ of certiorari to be heard by the Supreme Court or return to the district court to argue the case under the guidelines set in the appeals court decision. No ruling yet has ordered a halt to Whole Foods' $565 million purchase of Wild Oats, which was completed in September 2007 (2"The Tan Sheet" Sept. 3, 2007, In Brief)...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.